<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05061771</url>
  </required_header>
  <id_info>
    <org_study_id>AK802</org_study_id>
    <nct_id>NCT05061771</nct_id>
  </id_info>
  <brief_title>Nomacopan Therapy in Adult Patients With Bullous Pemphigoid Receiving Adjunct Oral Corticosteroid Therapy (ARREST-BP)</brief_title>
  <acronym>ARREST-BP</acronym>
  <official_title>A Randomized, Part A Partial Blinded and Part B Double Blinded, Placebo-controlled 24-week Clinical Study to Evaluate the Efficacy and Safety of Nomacopan Therapy in Adult Patients With Bullous Pemphigoid Receiving Adjunct Oral Corticosteroid Therapy (ARREST-BP)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AKARI Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AKARI Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A phase III two-part study of nomacopan, a bifunctional inhibitor of complement component C5&#xD;
      and leukotriene B4 (LTB4), for the treatment of moderate and severe bullous pemphigoid. There&#xD;
      is evidence that both terminal complement activation (via C5) and the lipid mediator LTB4 may&#xD;
      have a central role in driving the disease. In this study patients will be randomized to&#xD;
      receive either nomacopan plus oral corticosteroids (OCS) or placebo plus OCS for a treatment&#xD;
      period of 24 weeks. OCS will be tapered over the course of the treatment if the symptoms of&#xD;
      disease improve.&#xD;
&#xD;
      Part A the 4-arm study in 48 patients will compare two different doses of nomacopan with&#xD;
      placebo and is anticipated to complete and report in March 2023.&#xD;
&#xD;
      Part B the confirmatory 2-arm study in approximately 100 patients will compare a single dose&#xD;
      of nomacopan with placebo and is anticipated to complete and report in June 2025.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2021</start_date>
  <completion_date type="Anticipated">June 2025</completion_date>
  <primary_completion_date type="Anticipated">December 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Achievement of Complete Disease Remission</measure>
    <time_frame>weeks 16 - 24</time_frame>
    <description>Proportion of patients in Complete Disease Remission</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cumulative oral corticosteroid, OCS, during treatment</measure>
    <time_frame>Randomization to 24 weeks</time_frame>
    <description>Cumulative OCS used during treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients requiring rescue therapy</measure>
    <time_frame>Randomization to 24 weeks</time_frame>
    <description>Proportion of patients requiring rescue therapy during the 24 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Achievement Partial Disease Remission</measure>
    <time_frame>weeks 16 - 24</time_frame>
    <description>Proportion of patients in Partial Disease Remission</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to onset of Complete Disease Remission</measure>
    <time_frame>week 6 to 24</time_frame>
    <description>Time (weeks) to onset of Complete Disease Remission</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Complete and Partial Disease Remission</measure>
    <time_frame>week 6 to 24</time_frame>
    <description>Duration (weeks) of Complete Disease Remission and Partial Disease Remission</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigator Global Assessment (IGA) score</measure>
    <time_frame>weeks 6 - 24</time_frame>
    <description>Proportion of patients with Investigator Global Assessment (IGA) score of 0 or 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Day 1 to Week 28</time_frame>
    <description>Frequency, type and relationship of AEs to treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Steroid-related AEs</measure>
    <time_frame>Day 1 to Week 28</time_frame>
    <description>Incidence of steroid-related AEs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dermatology Life Quality Index (DLQI)</measure>
    <time_frame>Randomisation to week 24</time_frame>
    <description>Change from baseline in Dermatology Life Quality Index (DLQI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment-emergent anti-drug antibody (ADA) responses and titre and neutralising potential assessed in vitro at baseline and every 4 weeks</measure>
    <time_frame>Day 1 to Week 28</time_frame>
    <description>Incidence of treatment-emergent anti-drug antibody (ADA) responses and titre and neutralising potential assessed in vitro at baseline and then every 4 weeks</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">148</enrollment>
  <condition>Bullous Pemphigoid</condition>
  <arm_group>
    <arm_group_label>nomacopan (rVA576)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>PART A:&#xD;
High dose nomacopan (standard complement ablating doses on Day 1 followed by 45 mg qd) administered by subcutaneous injection, plus a starting dose of 0.5 mg/kg/day OCS qd&#xD;
or&#xD;
Low dose nomacopan (standard complement ablating doses on Day 1 followed by 15 mg qd) administered by subcutaneous injection, plus a starting dose of 0.5 mg/kg/day OCS&#xD;
PART B:&#xD;
Nomacopan (standard complement ablating doses on Day 1 followed by to be confirmed mg qd) administered by subcutaneous injection, plus a starting dose of 0.5 mg/kg/day OCS qd</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>PART A:&#xD;
Placebo (matching standard complement ablating doses on Day 1 and then matching injection volume of 45mg dose qd) administered by subcutaneous injection, plus a starting dose of 0.5 mg/kg/day oral corticosteroid (OCS) qd&#xD;
or&#xD;
Placebo (matching standard complement ablating doses on Day 1 and then matching injection volume of 15mg dose qd) administered by subcutaneous injection, plus a starting dose of 0.5 mg/kg/day oral corticosteroid (OCS) qd&#xD;
PART B:&#xD;
Placebo (matching standard complement ablating doses on Day 1 and then matching injection volume of active dose qd) administered by subcutaneous injection, plus a starting dose of 0.5 mg/kg/day oral corticosteroid (OCS) qd</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nomacopan (rVA576)</intervention_name>
    <description>Nomacopan an inhibitor of complement C5 and LTB4</description>
    <arm_group_label>nomacopan (rVA576)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female between 18 and 89 years of age inclusive at the time of consent with&#xD;
             Karnofsky score of 50% or more at screening&#xD;
&#xD;
          2. Male or female ≥90 years of age at the time of consent with Karnofsky score of 70% or&#xD;
             more at screening&#xD;
&#xD;
          3. Diagnosis of Bullous Pemphigoid either newly diagnosed or relapsing&#xD;
&#xD;
          4. Patients with confirmed atypical Bullous Pemphigoid&#xD;
&#xD;
          5. Bullous Pemphigoid classified as either moderate or severe on the basis of the&#xD;
             Investigator Global Assessment (IGA) at randomisation&#xD;
&#xD;
          6. Willing to receive immunisation against Neisseria meningitidis and/or antibiotic&#xD;
             prophylaxis&#xD;
&#xD;
          7. Provision of voluntary written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with recalcitrant BP that have never achieved CDA or who have never been in&#xD;
             complete disease remission despite long term treatment with super potent topical&#xD;
             steroid or oral cotricosteroid&#xD;
&#xD;
          2. Epidermolysis bullosa acquisita, mucous membrane pemphigoid, or anti p200 pemphigoid&#xD;
&#xD;
          3. Mucosal lesions BPDAI score accounts for ≥30% of total BPDAI activity score at&#xD;
             randomisation&#xD;
&#xD;
          4. BP considered to be drug induced, in particular diagnosis of BP made within two months&#xD;
             of starting a drug well known to induce BP&#xD;
&#xD;
          5. Treatment with BP-directed biologics including: a) Any cell-depleting agents&#xD;
             including, but not limited to, rituximab within 12 months prior to baseline, b) Other&#xD;
             biologics within five half-lives (if known) or 16 weeks prior to the baseline,&#xD;
             whichever is longer, or c) Intravenous immunoglobulin within 16 weeks prior to the&#xD;
             baseline.&#xD;
&#xD;
          6. Taking &gt; 0.3 mg/kg/day OCS at screening&#xD;
&#xD;
          7. Treatment with systemic immunomodulators such as dapsone or doxycycline within four&#xD;
             half-lives of the drugs prior to baseline Day 1&#xD;
&#xD;
          8. Treatment with immunosuppressants within the last two weeks prior to baseline&#xD;
&#xD;
          9. Treatment with an anti-complement therapy or with Zileuton within the last three&#xD;
             months prior to baseline&#xD;
&#xD;
         10. OCS dose no more than 0.3mg/kg/day in the 7 days before screening visit&#xD;
&#xD;
         11. Taking super-potent topical corticosteroids and unable to discontinue them at or&#xD;
             before the screening assessment&#xD;
&#xD;
         12. Active systemic or organ system bacterial or fungal infection or progressive severe&#xD;
             infection&#xD;
&#xD;
         13. Known congenital immunodeficiency or a history of acquired immunodeficiency including&#xD;
             a positive human immunodeficiency virus (HIV) test&#xD;
&#xD;
         14. Active infection with hepatitis B or C&#xD;
&#xD;
         15. Positive nasal throat swab for Neisseria species&#xD;
&#xD;
         16. Known hypersensitivity to nomacopan and any of its excipients&#xD;
&#xD;
         17. Receipt of live attenuated vaccines within 2 weeks of Day 1&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sanjeev Khindri</last_name>
    <phone>+44 020 8004 0261</phone>
    <email>Sanjeev.Khindri@akaritx.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Miles Nunn</last_name>
    <phone>+44 020 8004 0261</phone>
    <email>Miles.Nunn@akaritx.com</email>
  </overall_contact_backup>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 15, 2021</study_first_submitted>
  <study_first_submitted_qc>September 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 30, 2021</study_first_posted>
  <last_update_submitted>September 27, 2021</last_update_submitted>
  <last_update_submitted_qc>September 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pemphigoid</keyword>
  <keyword>blistering skin disease</keyword>
  <keyword>nomacopan</keyword>
  <keyword>complement</keyword>
  <keyword>leukotriene</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pemphigoid, Bullous</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

